<?xml version="1.0" encoding="UTF-8"?>
<xml>
<records>
<record>
  <contributors>
    <authors>
      <author>Kim, H. U.</author>
      <author>Alten, R.</author>
      <author>Avedano, L.</author>
      <author>Dignass, A.</author>
      <author>Gomollón, Fernando</author>
      <author>Greveson, K.</author>
      <author>Halfvarson, J.</author>
      <author>Irving, P. M.</author>
      <author>Jahnsen, J.</author>
      <author>Lakatos, P. L.</author>
      <author>Lee, J. H.</author>
      <author>Makri, S.</author>
      <author>Parker, B.</author>
      <author>Peyrin-Biroulet, L.</author>
      <author>Schreiber, S.</author>
      <author>Simoens, S.</author>
      <author>Westhovens, R.</author>
      <author>Danese, S.</author>
      <author>Jeong, J. H.</author>
    </authors>
  </contributors>
  <titles>
    <title>The Future of Biosimilars: Maximizing Benefits Across Immune-Mediated Inflammatory Diseases</title>
    <secondary-title>Drugs</secondary-title>
  </titles>
  <doi>10.1007/s40265-020-01256-5</doi>
  <pages/>
  <volume/>
  <number/>
  <dates>
    <year>2020</year>
    <pub-dates>
      <date>2020</date>
    </pub-dates>
  </dates>
  <abstract/>
</record>

</records>
</xml>